🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In the latest episode of Life Science Cares Boston "Moving Forward, Giving Back" podcast, our President & CEO Sarah Boyce highlights Avidity’s involvement in #LifeScienceShares and our commitment to make a meaningful difference in the San Diego community. Listen here: lifesciencecares.org/podcast/

Tomorrow during a presentation at #JPM2025 in San Francisco, our President and CEO, Sarah Boyce, will share Avidity’s vision for the future and our commitment to transforming the lives of people living with rare diseases.

We are excited to announce the appointment of Kat Lange as Chief Business Officer. With a proven track record in biotech investment banking, her expertise will be key as we advance a new class of RNA therapeutics to improve patients’ lives. Learn more: aviditybiosciences.investorroom.com/2025-01-08-Avi…

If you are interested in joining our #BeAVID team, stop by our careers page to check out our open positions. We are looking for exceptional people to become part of our fun and innovative team. Explore our current opportunities: aviditybiosciences.com/careers/

Today, we honor Dr. Martin Luther King Jr.'s legacy and his vision for equity, justice, and acceptance. As we reflect on his powerful impact, we reaffirm our commitment to advancing his vision through our #BeAVID values and fostering inclusion, respect, and equality for all.

We’re excited to announce that Eric Mosbrooker, our current Chief Strategy Officer, will transition to the role of Chief Commercial Officer. We look forward to his continued leadership as we strengthen our global infrastructure. Learn more: aviditybiosciences.investorroom.com/2025-01-08-Avi…

Avidity's Hanhua Huang, PhD, will present at the RNAi-Based Therapeutics Summit to discuss how we have utilized our proprietary AOC platform to advance clinical programs for rare neuromuscular diseases and in precision #cardiology. Learn more: aviditybiosciences.com/pipeline/pipel…

#PRKAG2 syndrome is a rare, inherited cardiac disease. At Avidity, we are applying the versatility of our AOC™ platform to target the underlying causes of genetic #heartdiseases within precision #cardiology. Learn more in our recent volume: aviditybiosciences.investorroom.com/events-and-pre…

Avidity’s Ching Chang, Ernest Chow, and Sarah Hudson are speaking at Why Summits’ American Strategic Portfolio Management in Life Sciences – West Coast conference! Hear their insights on portfolio strategy in life sciences. Learn more: whysummits.com/american-strat…

Wishing a joyful and prosperous Year of the Snake to all those celebrating #LunarNewYear.

Celebrating #BlackHistoryMonth, we honor the individuals who’ve shaped history, culture, and progress. At Avidity, we remain committed to fostering diversity, inclusion, and opportunity - empowering the next generation of innovators to make a difference. #BHM2025

February is #AmericanHeartMonth. We stand in solidarity with those affected by rare genetic cardiomyopathies and reaffirm our commitment to advancing our innovative RNA therapeutic candidates for precision cardiology to profoundly improve the lives of patients.

On #February11, we celebrate International Day of Women & Girls in Science. As a woman-led organization, we champion the incredible women shaping the future of science. Join us in celebrating their achievements and empowering the next generation of female leaders in #biotech.

In honor of #DuchenneAwarenessWeek, we’re proud to share the inspiring stories of Nathan, Lee, & their families as they navigate life with DMD. Thank you for courageously sharing your journeys to raise awareness and educate others about this #raredisease: aviditybiosciences.com/patients/

We are proud to support EveryLife Foundation’s #RareDiseaseWeek on Capitol Hill, taking place February 24-26. This event brings together #raredisease advocates from across the country to make their voices heard by members of Congress. Learn more: everylifefoundation.org/rare-advocates… #RAREDC2025

During @BioComCA’s Global Life Science Partnering and Investor Conference, our President and CEO Sarah Boyce will participate in a panel discussion focusing on the evolving landscape of drug discovery targeting RNA. See the agenda: biocom.org/conferences/gl…

We are proud to support Jett Foundation’s 8th Annual #RareDiseaseDay Virtual Event. Join us to hear firsthand how the Duchenne community is living life to the fullest, breaking barriers, and embracing new opportunities: jettfoundation.org/rare-disease-d… #ThrivingwithDuchenne

Today we announced that we will be presenting one oral and two poster presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, taking place March 16-19. See our press release for more information: aviditybiosciences.investorroom.com/2025-03-12-Avi…

We are pleased to announce that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation to our AOC in clinical development myotonic dystrophy type 1 (#DM1). See our press release: aviditybiosciences.investorroom.com/2025-04-08-Avi…

Join our management team for a #firesidechat during the Needham Healthcare Conference to learn more about the exciting progress we are making with our three clinical programs for #DM1, #DMD44 and #FSHD and our expansion into precision #cardiology: aviditybiosciences.investorroom.com/events-and-pre…